Amsbio has expanded its diverse range of recombinant and monoclonal antibodies to include over 10,000 new validated monospecific products in 15,000 formulations to support research in cancer, immunology, neuroscience, and signal transduction.
Every antibody in the new catalogue has been subject to rigorous validation technologies to confirm that they selectively recognize their intended targets across applications such as immunohistochemistry, western blot, flow cytometry and immunofluorescence. These recombinant and monoclonal antibodies also provide high sensitivity and minimal background…
Strengthens Board with experienced industry executive, specializing in strategic planning, organizational leadership and commercial execution
Cambridge, UK, 16 June 2026 – Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today announced the appointment of Bruce Eaton, PhD as Chairman of the Board, with immediate effect. The appointment aligns with the Company’s strategic growth objectives following recent senior leadership changes1, to drive global commercialization of the INDUCE-seq…
Cresset has released Flare V12, a new version of its computer-aided drug design (CADD) solution for the discovery, design and optimization of small molecules. Flare V12 is focussed on improving access to Free Energy Perturbation (FEP) in drug discovery.FEP is used to predict how strongly drug candidates bind to their targets, helping guide compound selection. However, despite its recognised accuracy, adoption has often been limited by computational cost, usability barriers and challenges in modeling complex chemical transformations.Flare V12 is designed to address these challenges.Reducing…
Here's some exciting news about the Cambridge Stock Exchange Project (CSEP).
The Cambridge Stock Exchange Project is creating a platform for accessing liquidity from the market inside high-density innovation ecosystems across the UK.
You can also learn more about the initiative on the Cambridge Stock Exchange Project website.
Sandwich, UK — 10 June 2026: Discovery Park, Kent’s science and innovation hub, has launched the seventh edition of its Discovery Spark accelerator programme, welcoming 12 startups to its campus in Sandwich.
The seventh cohort is themed around innovations in health, with startups selected based on the need for their innovation, the uniqueness of their solution, and the strength of their team. Throughout June, the selected founders will be attending specialist-led sessions in both Kent and London, focused on investor readiness, covering essential business topics from tax and finance,…
· Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1
· Comprehensive preclinical data package demonstrates differentiating oral activity and CNS penetration, unlocking treatment of primary and secondary brain cancers
· Dr Gabriel Fox appointed as Chief Medical Officer to lead clinical development
Cambridge, UK: PhoreMost Limited (“PhoreMost”), a biotech company focused on turning scientific breakthroughs into life-changing…
Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease
Two-year programme expands Harness' neurodegenerative disease pipeline, leveraging proprietary MISBA® platform
Cambridge, UK, 9 June 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces it has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (…
Amsbio announce the availability of fresh whole blood products from diverse, healthy donors now with overnight delivery in the US, Europe and the UK in conjunction with sister company - Research Donors. All these premium human blood biospecimens undergo rigorous serology screening and rapid processing to ensure maximum viability.
Supplied with donor diversity data including age, sex, blood type and other characteristics, all fresh blood products come fully consented with compliance documentation for genetic analysis, biomarker discovery and commercial research.
Sourcing blood products for…
Deep Science Ventures (DSV), a UK-based deeptech venture creator, and Medicines Discovery Catapult (MDC), a life sciences service dedicated to turning drug discovery into commercial breakthroughs, today announced a strategic collaboration to address challenges in delivering medicines into the brain.
One of medicine’s greatest challenges is ensuring that treatments reach the precise area of the body where they are needed. While recent scientific breakthroughs have identified numerous targets for neurological conditions, the difficulty of effectively transporting these treatments across the…
Appointments bring deep commercial, scaling, life science, healthcare, and diagnostics expertise to accelerate growth and delivery of clinical impactOxford, UK – 3 June 2026 – PrecisionLife, a leader in AI-driven precision medicine for chronic diseases, today announced the appointments of Dr Pradip Banerjee, PhD, MBA, as an Independent Non-Executive Director and Dr Kam Pooni, PhD, as Chief Product Officer. These strategic hires further strengthen the company’s leadership as it scales from a pioneering technology innovator to a commercial organization delivering real-world healthcare impact.Dr…